A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
Clinical trial NCT03844256 · UNKNOWN
Trial details
- NCT number
- NCT03844256
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-07
- Primary completion
- 2024-07-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.